At this time, a generic version of Tribenzor (olmesartan medoxomil/amlodipine/hydrochlorothiazide) is not available. The first patent for this medication is set to expire in October 2016, which is the earliest possible date that a generic version of the drug could become available. However, lawsuits or other patents for specific uses of the medication could delay the production of a generic Tribenzor.
Tribenzor is made by Daiichi Sankyo Europe GmbH for Daiichi Sankyo, Inc. It is currently under the protection of a patent, as well as exclusivity rights, that prevent any generic Tribenzor from being manufactured in the United States.
When Will a Generic Version Be Available?
The first patent for Tribenzor expires in October 2016. This is the earliest predictable date that a generic version could become available.
However, there are other circumstances that could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Tribenzor uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Tribenzor medication.
Is It Cheaper to Take Olmesartan, Amlodipine, and Hydrochlorothiazide Separately?
It depends on your individual situation. For some people, taking the combination product Tribenzor is less expensive than taking the three individual medications. This may be especially true for many people who have insurance coverage, and pay a co-pay for each of their medicines. These people will only have to pay one co-pay for Tribenzor instead of three co-pays if the Tribenzor components are taken separately.
However, this may not be true for all situations. If cost is a concern for you, be sure to ask your pharmacist about the least expensive way to obtain your medications.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Tribenzor [package insert]. Parsippany, New Jersey: Daiichi Sankyo, Inc.;2013 July.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed September 20, 2010.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click